EyePoint (EYPT) Capital Expenditures (2010 - 2026)
EyePoint (EYPT) posted Capital Expenditures of $99000.0 for Q1 2026, down 96.9% sequentially from $3.2 million in Q4 2025, and up 125.0% YoY from $44000.0 in Q1 2025.
EyePoint (EYPT) Capital Expenditures (2010 - 2026) Analysis & Trends
EyePoint has reported Capital Expenditures for 17 years, with the latest figure at $99000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 125.0% year-over-year to $99000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 6.35% YoY) and the FY2025 annual result came in at $3.3 million, down 19.05% from the prior year.
- Capital Expenditures declined to $99000.0 in Q1 2026 per EYPT's latest filing, from $3.2 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $3.2 million in Q4 2025 and troughed at -$484000.0 in Q2 2023.
- A 5-year average of $638733.3 and a median of $218000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 814.5% in 2022, then slumped 322.02% in 2023.
- Over 5 years, Capital Expenditures stood at $585000.0 in 2022, then sank by 182.74% to -$484000.0 in 2023, then jumped by 436.78% to $1.6 million in 2024, then jumped by 95.95% to $3.2 million in 2025, then slumped by 96.9% to $99000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $99000.0, $3.2 million, and $24000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 64,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64,000.00 |
| Jun 30, 2026 | 64,000.00 |
| Mar 31, 2026 | 99,000.00 |
| Mar 31, 2026 | 99,000.00 |
| Dec 31, 2025 | 3.19 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 1.63 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | -315,000.00 |
| Jun 30, 2024 | -315,000.00 |
| Mar 31, 2024 | 535,000.00 |
| Mar 31, 2024 | 535,000.00 |